排序方式： 共有5条查询结果，搜索用时 31 毫秒
1
1.
Habibollahi Peiman Shin Benjamin Shamchi Sara P. Wachtel Heather Fraker Douglas L. Trerotola Scott O. 《Cardiovascular and interventional radiology》2018,41(1):63-72
CardioVascular and Interventional Radiology - Parathyroid venous sampling (PAVS) is usually reserved for patients with persistent or recurrent hyperparathyroidism after parathyroidectomy with... 相似文献
2.
3.
Peiman Habibollahi Sara Pourhassan Shamchi John M. Choi Terence P. Gade S. William Stavropoulos Stephen J. Hunt Mandeep Dagli Deepak Sudheendra Jeffery I. Mondschein Michael C. Soulen Gregory J. Nadolski 《Journal of vascular and interventional radiology : JVIR》2019,30(3):323-329
Purpose
To evaluate long-term outcomes of patients with hepatocellular carcinoma (HCC) who show a complete response (CR) vs non-CR on pretransplantation imaging studies or pathologic evaluation of liver explants after locoregional therapy (LRT) before liver transplantation.Materials and Methods
Patients listed for liver transplantation for HCC (March 1998 to December 2010) undergoing LRT with available multiphase MR/CT imaging before transplantation were included. Pathologic response was evaluated based on liver explant pathology. A total of 108 patients (17 women; 16%) met the inclusion criteria.Results
Radiologic CR was achieved in 65 patients (60%) vs non-CR in 43 (40%), and pathologic CR was achieved in 36 patients (33%) vs non-CR in 72 (67%). Mean 5-year overall survival (OS) from the time of listing and recurrence-free survival (RFS) after liver transplantation were significantly better for patients with pathologic CR vs non-CR on explant pathology (OS, 83.3% vs 65.2% [28% difference; P = .046]; RFS, 80.6% vs 62.5% [29% difference; P = .045]). Mean 5-y OS and RFS were not significantly different between patients with radiologic CR or non-CR on pretransplantation imaging (OS, 75.4% vs 65.1% [P = .12]; RFS, 74% vs 62.8% [P = .17]).Conclusions
Achievement of a pathologic CR vs non-CR in response to LRT before liver transplantation for HCC is associated with improved OS from time of listing and improved RFS after liver transplantation. However, current imaging paradigms fall short of accurate delineation of response to LRT, resulting in poor correlation of outcomes between pathologic and radiologic CR. 相似文献4.
Paydary Koosha Seraj Siavash Mehdizadeh Zadeh Mahdi Zirakchian Emamzadehfard Sahra Shamchi Sara Pourhassan Gholami Saeid Werner Thomas J. Alavi Abass 《Molecular imaging and biology》2019,21(1):1-10
Molecular Imaging and Biology - The applications of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/X-ray computed tomography (PET/CT) in the management of patients with breast cancer... 相似文献
5.
Peiman Habibollahi Sara P. Shamchi Rashmi Tondon Brett L. Ecker Terence P. Gade Stephen Hunt Michael C. Soulen Emma E. Furth Matthew H. Levine Gregory Nadolski 《Journal of vascular and interventional radiology : JVIR》2018,29(2):237-243
Purpose
To examine differences in outcome and response of cirrhotomimetic (CMM) hepatocellular carcinoma (HCC) to a combination of bridging transcatheter arterial chemoembolization and orthotopic liver transplantation (OLT) compared with non-CMM HCC.Materials and Methods
All patients with pathologically proven CMM HCC who underwent bridging transcatheter arterial chemoembolization before OLT between 2007 and 2013 (n = 23) were retrospectively compared with a control group of patients with pathologically proven non-CMM HCC (n = 46).Results
There were 29 tumors in the CMM HCC group and 64 tumors in the non-CMM group identified and treated. Objective response rate on MR imaging at 1 and 3 months after transcatheter arterial chemoembolization for CMM HCC tumors (including patients with complete and partial response) was 93.1% and 86.4% compared with 85.2% and 93.2% for non-CMM tumors without statistically significant difference (P = .54 and P = .09, respectively). Pathologic study of liver explants showed complete tumor necrosis in 62.3% of non-CMM tumors (38/61) compared with 10.3% of CMM tumors (3/29) (P < .0001). Overall 2-year survival after transcatheter arterial chemoembolization and OLT was significantly lower for patients with CMM HCC compared with patients non-CMM HCC (65.2% vs 87%, P = .03). Patients with CMM HCC with extranodular tumor extension involving > 50% of liver parenchyma had worse survival with mean 2-year survival of 402 days ± 102 vs 656 days ± 39 for the remaining patients with CMM HCC (P = .02).Conclusions
Despite similar early imaging response rates, CMM HCC tumors had markedly lower rates of complete pathologic necrosis on liver explants and were associated with reduced survival after OLT compared with conventional HCCs. 相似文献
1